Terazosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Terazosin
- Terazosin: From Hypertension and Benign Prostatic Hyperplasia to Hypotrichosis Simplex of the Scalp
Terazosin: From Hypertension and Benign Prostatic Hyperplasia to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Terazosin is an alpha-1 adrenergic receptor antagonist classically used for conditions such as hypertension and benign prostatic hyperplasia (BPH); detailed original-indication and mechanism-of-action documentation for this evidence pack is currently a data gap. The TxGNN model’s top-ranked prediction is Hypotrichosis Simplex of the Scalp, but this specific prediction is currently supported by 0 clinical trials and 0 publications — it is a knowledge-graph score with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (drug-level MOA/indication data flagged as gaps — see DG001, DG002). Terazosin’s well-established classical use as an alpha-1 blocker is hypertension and BPH. |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the drug-level record of this evidence pack (data gap DG002). However, the repurposing rationale attached to every candidate indication consistently describes terazosin as an alpha-1 adrenergic receptor antagonist, acting mainly through vasodilation and relaxation of vascular/prostatic smooth muscle — consistent with its classical clinical role in hypertension and BPH.
For the top-ranked prediction, hypotrichosis simplex of the scalp, the evidence pack’s own mechanistic assessment states there is no known mechanistic link between this condition and alpha-1 blockade: hypotrichosis simplex of the scalp is an autosomal hereditary disorder of hair follicle development, whereas terazosin’s pharmacology operates on vascular and smooth-muscle tone. The rationale explicitly notes this is “a high-scoring TxGNN knowledge-graph prediction, without mechanistic support.”
For context, the same evidence pack contains other candidate indications for terazosin with considerably stronger — though still limited — mechanistic and literature support, notably Raynaud disease (alpha-1 blockade directly addresses the peripheral vasospasm that is the core pathology) and migraine prophylaxis (explored clinically since the 1990s via modulation of intracranial vascular tone). These are not the top-ranked candidate by TxGNN score, but they carry stronger rationale and should be considered if this repurposing programme is prioritised by mechanistic plausibility rather than score alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Terazosin does not currently hold a marketing authorisation in the UK, and no licence records are present in this evidence pack (0 licences on record).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Drug-level safety documentation (key warnings, contraindications) and formal DDI data were not retrievable at the time of this evidence pack and are flagged as a blocking data gap (DG001) requiring resolution before any safety-relevant decision can be made.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (hypotrichosis simplex of the scalp) has no supporting clinical trials, no supporting literature, and no plausible mechanistic link according to the evidence pack’s own assessment — this places it at Evidence Level L5 (model prediction only), which does not support advancement.
To proceed, the following is needed:
- Resolution of blocking data gap DG001 (UK/MHRA-equivalent product labelling: warnings, contraindications, DDI)
- Resolution of high-severity data gap DG002 (confirmed mechanism of action from an authoritative source such as DrugBank)
- Documentation of terazosin’s approved original indication(s) for this evidence pack
- If pursuing repurposing further, consider re-scoping toward the higher-rationale candidates in this same batch (Raynaud disease, evidence level L3; migraine prophylaxis, evidence level L3) rather than the top TxGNN-score candidate, given their stronger mechanistic and historical clinical support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.